IPO Issue Details
Issue Price / Price Band₹1,062 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size14 Shares per Lot
Total Issue Size61,71,101 shares (aggregating up to ₹655.37 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryOffer For Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenMon, 08 Dec 2025
Subscription CloseWed, 10 Dec 2025
Anchor AllotmentSun, 07 Dec 2025
Basis of AllotmentThu, 11 Dec 2025
Initiation of RefundsFri, 12 Dec 2025
Credit of Shares to DematFri, 12 Dec 2025
Listing DateMon, 15 Dec 2025
UPI Mandate Deadline2025-12-10
Application & Investment Details
Retail — Min (1 Lots)₹14,868 — 14 shares
Retail — Max (13 Lots)₹193,284 (13 Lots)
HNI — Min (68 Lots)₹10,11,024 — 952 shares
EPS (Pre-IPO)₹24.43
EPS (Post-IPO)₹30.21
P/E Ratio (Pre-IPO)43.47x
P/E Ratio (Post-IPO)35.15x
Pre-IPO Promoter Holding6,11,60,088 shares
Post-IPO Promoter Holding6,11,60,088 shares
About Corona Remedies Ltd. Address
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.Competitive Strength:Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.Qualified, experienced and entrepreneurial management team supported by marquee investors.
Objects of the Issue
Corona Remedies Ltd. Address proposes to utilise the net proceeds from the Issue for the following objects:
1
BRLMs fees and commissions (including underwriting commission, brokerage and selling commission)
21.03
2
Fees payable to the Registrar to the Offer
0.50
3
Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs
3.07
4
Advertising and marketing expenses
2.41
5
Others: Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees
7.11
6
Other regulatory expenses
1.17
7
Fees payable to legal counsels, statutory auditors, independent chartered accountants, practising company secretary, intellectual property consultants, industry service provider and others
8.81
8
Printing and distribution of issue stationery
4.01
Shareholding & Lock-in
Pre-IPO Promoter Holding
6,11,60,088 shares
Post-IPO Promoter Holding
6,11,60,088 shares
